Top

Published in:

01-06-2018 | Original Article

Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis

Authors: Claudio Luchini, Nicola Veronese, Alessia Nottegar, Monica Cheng, Takuma Kaneko, Camilla Pilati, Fabrizio Tabbò, Brendon Stubbs, Antonio Pea, Fabio Bagante, Jacopo Demurtas, Matteo Fassan, Maurizio Infante, Liang Cheng, Aldo Scarpa

Published in: Virchows Archiv | Issue 6/2018

Abstract

Extranodal extension (ENE) of nodal metastasis is defined as the extension of metastatic cells through the nodal capsule into the perinodal tissue. This morphological parameter, recently proposed as an important prognostic factor in different types of malignancy, has not been included in the TNM staging system for non-small cell lung cancer (NSCLC). In this systematic review with meta-analysis, we weighted the prognostic role of ENE in patients with lymph node-positive NSCLC. Two independent authors searched SCOPUS and PubMed through 28 February 2017. Prospective and retrospective studies on NSCLC, comparing patients with presence of ENE (ENE+) ENE+) vs. only intranodal extension (ENE–) and including data regarding prognosis, were considered as eligible. Data were summarized using risk ratios (RR) for the number of deaths/recurrences, and hazard ratios (HR) with 95% confidence intervals (CI) for time-dependent risk related to ENE+, adjusted for potential confounders. We identified 13 studies, including 1709 patients (573 ENE+ and 1136 ENE–) with a median follow-up of 60 months. ENE was associated with a significantly increased risk of mortality of all causes (RR = 1.39, 95% CI: 1.18–1.65, P < 0.0001, I² = 70%; HR = 1.30, 95% CI: 1.01–1.67, P = 0.04, I² = 0%) and of disease recurrence (RR = 1.32, 95% CI: 1.04–1.68, P = 0.02, I² = 42%; HR = 1.93, 95% CI: 1.53–2.44, P < 0.0001, I² = 0%). We conclude that in NSCLC, requirements for assessment of ENE should be included in gross sampling and ENE status should be included in the pathology report. Inclusion of ENE status in oncology staging systems will allow further assessment of its role as prognostic parameter.

Available only for authorised users

Travis WD, Brambilla E, Burke AP, Marx A (2015) WHO classification of tumours of the lung, pleura, thymus, and heart, 4th edn. IARC Press, Lyon

Rami-Porta R, Asamura H, Travis WD, Rusch VW (2017) Lung cancer—major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(2):138–155. https://doi.org/10.3322/caac.21390 CrossRefPubMed

Torre LA, Siegel RL, Jemal A (2016) Lung cancer statistics. Adv Exp Med Biol 893:1–19. https://doi.org/10.1007/978-3-319-24223-1_1 CrossRefPubMed

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. https://doi.org/10.3322/caac.21262 CrossRefPubMed

Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Brawley OW, Wender RC (2017) Cancer screening in the united states, 2017: a review of current American Cancer Society guidelines and current issues in cancer screenings. CA Cancer J Clin 67(2):100–121. https://doi.org/10.3322/caac.21392 CrossRefPubMed

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging manual 7^th ed. Springer-Verlag, New York

Amin MB, Edge SB, Greene FL (2017) AJCC cancer staging manual 8^th ed. Springer-Verlag, New York. https://doi.org/10.1007/978-3-319-40618-3 CrossRef

Tamura M, Matsumoto I, Saito D, Yoshida S, Takata M, Takemura H (2016) Lymph node ratio as a prognostic factor in patients with pathological N2 non-small cell lung cancer. World J Surg Oncol 14(1):295. https://doi.org/10.1186/s12957-016-1048-5 CrossRefPubMedPubMedCentral

Han H, Chen H (2017) Selective lymph node dissection in early-stage non-small cell lung cancer. J Thorac Dis 9(7):2102–2107. https://doi.org/10.21037/jtd.2017.06.04 CrossRefPubMedPubMedCentral

10.

Wind J, Lagarde SM, Ten Kate FJ, Ubbink DT, Bemelman WA, van Lanschot JJ (2007) A systematic review on the significance of extracapsular lymph node involvement in gastrointestinal malignancies. Eur J Surg Oncol 33(4):401–408. https://doi.org/10.1016/j.ejso.2006.11.001 CrossRefPubMed

11.

Luchini C, Veronese N, Pea A, Sergi G, Manzato E, Nottegar A, Solmi M, Capelli P, Scarpa A (2016) Extranodal extension in N1-adenocarcinoma of the pancreas and papilla of Vater: a systematic review and meta-analysis of its prognostic significance. Eur J Gastroenterol Hepatol 28(2):205–209. https://doi.org/10.1097/MEG.0000000000000520 PubMedCrossRef

12.

Veronese N, Nottegar A, Pea A, Solmi M, Stubbs B, Capelli P, Sergi G, Manzato E, Fassan M, Wood LD, Scarpa A, Luchini C (2016) Prognostic impact and implications of extracapsular lymph node involvement in colorectal cancer: a systematic review with meta-analysis. Ann Oncol 27(1):42–48. https://doi.org/10.1093/annonc/mdv494 CrossRefPubMed

13.

Luchini C, Nottegar A, Pea A, Solmi M, Stubbs B, Capelli P, Sergi G, Manzato E, Fassan M, Wood LD, Scarpa A, Veronese N (2016) Extranodal extension is an important prognostic parameter for both colonic and rectal cancer. Ann Oncol 27(5):955–956. https://doi.org/10.1093/annonc/mdw034 CrossRefPubMed

14.

Luchini C, Nottegar A, Pea A, Solmi M, Stubbs B, Capelli P et al (2016) Significance of the prognostic stratification of extranodal extension in colorectal cancer. Ann Oncol 27:1647PubMed

15.

Luchini C, Wood LD, Cheng L, Nottegar A, Stubbs B, Solmi M, et al (2016) Extranodal extension of lymph node metastasis is a marker of poor prognosis in oesophageal cancer: a systematic review with meta-analysis. J Clin Pathol

16.

Luchini C, Veronese N (2017) Extranodal extension of nodal metastasis is the main prognostic moderator in squamous cell carcinoma of the esophagus after neoadjuvant chemoradiotherapy. J Thorac Dis 9(10):3609–3612. https://doi.org/10.21037/jtd.2017.09.36 CrossRefPubMedPubMedCentral

17.

Veronese N, Fassan M, Wood LD, Stubbs B, Solmi B, Capelli P et al (2016) Extranodal extension of nodal metastases is a poor prognostic indicator in gastric cancer: a systematic review and meta-analysis. J Gastrointest Surg 20(10):1692–1698. https://doi.org/10.1007/s11605-016-3199-7 CrossRefPubMed

18.

Veronese N, Luchini C, Nottegar A, Kaneko T, Sergi G, Manzato E, Solmi M, Scarpa A (2015) Prognostic impact of extra-nodal extension in thyroid cancer: a meta-analysis. J Surg Oncol 112(8):828–833. https://doi.org/10.1002/jso.24070 CrossRefPubMed

19.

Luchini C, Veronese N (2017) The importance of extranodal extension in metastatic head and neck squamous cell carcinoma, in the light of the new AJCC cancer staging system. Oral Oncol 66:e1–e2CrossRefPubMed

20.

Mermod M, Tolstonog G, Simon C, Monnier Y (2016) Extracapsular spread in head and neck squamous cell carcinoma: a systematic review and meta-analysis. Oral Oncol 62:60–71. https://doi.org/10.1016/j.oraloncology.2016.10.003 CrossRefPubMed

21.

Luchini C, Fleischmann A, Boormans JL, Fassan M, Nottegar A, Lucato P, Stubbs B, Solmi M, Porcaro A, Veronese N, Brunelli M, Scarpa A, Cheng L (2017) Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis. Sci Rep 7(1):2374. https://doi.org/10.1038/s41598-017-02577-4 CrossRefPubMedPubMedCentral

22.

Ahn TS, Kim HS, Jeong CW, Kwak C, Kim HH, Ku JH (2015) Extracapsular extension of pelvic lymph node metastasis is an independent prognostic factor in bladder cancer: a systematic review and meta-analysis. Ann Surg Oncol 22(11):3745–3750. https://doi.org/10.1245/s10434-014-4359-1 CrossRefPubMed

23.

Nottegar A, Veronese N, Senthil M, Roumen RM, Stubbs B, Choi AH, Verheuvel NC, Solmi M, Pea A, Capelli P, Fassan M, Sergi G, Manzato E, Maruzzo M, Bagante F, Koç M, Eryilmaz MA, Bria E, Carbognin L, Bonetti F, Barbareschi M, Luchini C (2016) Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: a systematic review and an exploratory meta-analysis. Eur J Surg Oncol 42(7):919–925. https://doi.org/10.1016/j.ejso.2016.02.259 CrossRefPubMed

24.

Luchini C, Nottegar A, Solmi M, Sergi G, Manzato E, Capelli P, Scarpa A, Veronese N (2016) Prognostic implications of extranodal extension in node-positive squamous cell carcinoma of the vulva: A systematic review and meta-analysis. Surg Oncol 25(1):60–65. https://doi.org/10.1016/j.suronc.2015.09.005

25.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012CrossRefPubMed

26.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339(jul21 1):b2700. https://doi.org/10.1136/bmj.b2700 CrossRefPubMedPubMedCentral

27.

Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M The Newcastle-ottawa scale (NOS) for assessing the quality of nonradomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 30 Sept 2017

28.

Luchini C, Stubbs B, Solmi M, Veronese N (2017) Assessing the quality of studies in meta-analyses: advantages and limitations of the Newcastle Ottawa Scale. World J Meta-Anal 5(4):80–84. https://doi.org/10.13105/wjma.v5.i4.80 CrossRef

29.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188. https://doi.org/10.1016/0197-2456(86)90046-2 CrossRefPubMed

30.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558. https://doi.org/10.1002/sim.1186 CrossRefPubMed

31.

Xu H, Platt RW, Luo ZC, Wei S, Fraser WD (2008) Exploring heterogeneity in meta-analyses: needs, resources and challenges. Paediatr Perinat Epidemiol 22(Suppl 1):18–28. https://doi.org/10.1111/j.1365-3016.2007.00908.x CrossRefPubMed

32.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634. https://doi.org/10.1136/bmj.315.7109.629 CrossRefPubMedPubMedCentral

33.

Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56(2):455–463. https://doi.org/10.1111/j.0006-341X.2000.00455.x CrossRefPubMed

34.

Bergh NP, Schersten T (1965) Broncogenic carcinoma. Acta Chir Scand 347:1 (Suppl)

35.

Bollen EC, Theunissen PH, van Duin CJ, Drenth BM, van Noord JA, Blijham GH (1994) Clinical significance of intranodal and extranodal growth in lymph node metastases of non-small cell lung cancer. Scand J Thorac Cardiovasc Surg 28(3-4):97–102. https://doi.org/10.3109/14017439409099112 CrossRefPubMed

36.

Borghetti P, Barbera F, Bonu ML, Trevisan F, Ciccarelli S, Vitali P et al (2016) Resected pN1 non-small cell lung cancer: recurrence patterns and nodal risk factors may suggest selection criteria for post-operative radiotherapy. Radiol Med 121(9):696–703. https://doi.org/10.1007/s11547-016-0648-z CrossRefPubMed

37.

Feigenberg SJ, Hanlon AL, Langer C, Goldberg M, Nicolaous N, Millenson M et al (2007) A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer. J Thorac Oncol 2(4):287–292. https://doi.org/10.1097/01.JTO.0000263710.54073.b3 CrossRefPubMed

38.

Ishida T, Tateishi M, Kaneko S, Sugimachi K (1990) Surgical treatment of patients with nonsmall-cell lung cancer and mediastinal lymph node involvement. J Surg Oncol 43(3):161–166. https://doi.org/10.1002/jso.2930430308 CrossRefPubMed

39.

Larsson S (1976) Mediastinoscopy in bronchogenic carcinoma a study of 486 cases with special reference to the indications and limitations of the method. Scand J Thorac Cardiovasc Surg Suppl:1–23

40.

Lee YC, Wu CT, Kuo SW, Tseng YT, Chang YL (2007) Significance of extranodal extension of regional lymph nodes in surgically resected non-small cell lung cancer. Chest 131(4):993–999. https://doi.org/10.1378/chest.06-1810 CrossRefPubMed

41.

Liu W, Shao Y, Guan B, Hao J, Cheng X, Ji K, Wang K (2015) Extracapsular extension is a powerful prognostic factor in stage IIA-IIIA non-small cell lung cancer patients with completely resection. Int J Clin Exp Pathol 8(9):11268–11277PubMedPubMedCentral

42.

Macis G, Sallustio G, Minordi LM, Valentini V, Foschi R, Pirronti T (2000) Combined diagnostic imaging of mediastinal lymphadenopathy in lung cancer. Rays 25(4):447–462PubMed

43.

Moretti L, Yu DS, Chen H, Carbone DP, Johnson DH, Keedy VL, Putnam JB, Sandler AB, Shyr Y, Lu B (2009) Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy. Oncologist 14(11):1106–1115. https://doi.org/10.1634/theoncologist.2009-0130 CrossRefPubMed

44.

Shin S, Kim HK, Choi YS, Kim K, Kim J, Shim YM (2013) Prognosis of unexpected and expected pathologic N1 non-small cell lung cancer. Ann Thorac Surg 96(3):969–975; discussion 975–976. https://doi.org/10.1016/j.athoracsur.2013.04.070 CrossRefPubMed

45.

Suemasu K, Naruke T (1982) Prognostic significance of extranodal cancer invasion of mediastinal lymph nodes in lung cancer. Jpn J Clin Oncol 12:207–212

46.

Vansteenkiste JF, De Leyn PR, Deneffe GJ, Stalpaert G, Nackaerts KL, Lerut TE, Demedts MG (1997) Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group Ann Thorac Surg 63(5):1441–1450. https://doi.org/10.1016/S0003-4975(97)00314-7 CrossRefPubMed

47.

Sergeant G, Ectors N, Fieuws S, Aerts R, Topal B (2009) Prognostic relevance of extracapsular lymph node involvement in pancreatic ductal adenocarcinoma. Ann Surg Oncol 16:3070–3079CrossRefPubMed

48.

Lilo MT, Allison DB, Younes BK, Cui M, Askin FB, Gabrielson E et al (2017) The critical role of EBUS-TBNA cytology in the staging of mediastinal lymph nodes in lung cancer patients: a correlation study with positron emission tomography findings. Cancer 125:717–725

49.

Cetinkaya E, Usluer O, Yılmaz A, Tutar N, Çam E, Özgül MA, Demirci NY (2017) Is endobronchial ultrasound-guided transbronchial needle aspiration an effective diagnostic procedure in restaging of non-small cell lung cancer patients? Endosc Ultrasound 6(3):162–167. https://doi.org/10.4103/eus.eus_3_17 CrossRefPubMedPubMedCentral

50.

Depypere LP, Moons J, Mariette C, D'Journo XB, Thomas PA, Hölscher AH, et al (2017) Impact of extracapsular lymph node involvement after neoadjuvant chemoradiation therapy followed by surgery in carcinoma of the esophagus: a multicenter study. Ann Surg

51.

van Velzen E, Snijder RJ, Brutel de la Rivière A, Elbers HJ, van den Bosch JM (1996) Type of lymph node involvement influences survival rates in T1N1M0 non-small cell lung carcinoma. Lymph node involvement by direct extension compared with lobar and hilar node metastases. Chest 110(6):1469–1473CrossRefPubMed

52.

Nakagawa T, Okumura N, Kokado Y, Miyoshi K, Matsuoka T, Kameyama K (2007) Retrospective study of patients with pathologic N1-stage II non-small cell lung cancer. Interact Cardiovasc Thorac Surg 6(4):474–478. https://doi.org/10.1510/icvts.2007.154641 CrossRefPubMed

Title: Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis
Authors: Claudio Luchini
Nicola Veronese
Alessia Nottegar
Monica Cheng
Takuma Kaneko
Camilla Pilati
Fabrizio Tabbò
Brendon Stubbs
Antonio Pea
Fabio Bagante
Jacopo Demurtas
Matteo Fassan
Maurizio Infante
Liang Cheng
Aldo Scarpa
Publication date: 01-06-2018
Publisher: Springer Berlin Heidelberg
Published in: Virchows Archiv / Issue 6/2018
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-018-2309-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2018

Molecular defects in BRAF wild-type ameloblastomas and craniopharyngiomas—differences in mutation profiles in epithelial-derived oropharyngeal neoplasms

Book review—Diagnostic Pathology: Cytopathology, 2nd edition

Miniseries of reviews: gynecological pathology

The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer

Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients

The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future